GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: Example 161 [WO2011153942A1]
                                 
                                                         
                            Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: We obtained the chemical structure for sacibertinib from the WHO's proposed INN list 127 (21 July 2022). In this document it was described as a tyrosine kinase inhibitor and antineoplastic. This same chemical structure is claimed in patent WO2011153942A1 [1]. Inventions of this patent are described as inhibitors of erbB family receptor tyrosine kinases, in particular of EGFR and Her2 (ERBB2).
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| References | 
| 
                                                                         1. Zhang H, Chen Y, He Q. (2011)
                                         Cyanoquinoline derivatives. Patent number: WO2011153942A1. Assignee: Tianjin Hemei Biotechnology Co., Ltd.. Priority date: 09/06/2010. Publication date: 15/12/2011.  |